|
|
|
09190
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(Cooperative Group)
|
|
Title:
|
SWOG S06000: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FolFox, Optimox or Xelox
|
| | |
|
|
09119
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(Industrial)
|
|
Title:
|
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
|
| | |
|
|
07238
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(NCI Approved External Peer Review)
|
|
Title:
|
PHI-60 NCI#8063: A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction
|
| | |
|
|
06152
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(Cooperative Group)
|
|
Title:
|
CALGB/SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
|
| | |
|
|
05130
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(Institutional)
|
|
Title:
|
Evaluation of Colon/Rectal Cancer Patterns and Outcomes of Care
|
|